Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Redhill Biophrma ADR (NQ: RDHL )

0.4730 +0.0130 (+2.83%)
Streaming Delayed Price Updated: 11:40 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Redhill Biophrma ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
A Preview Of Redhill Biopharma's Earnings
Redhill Biopharma (NASDAQ:RDHL) will be releasing its next round of earnings this Thursday, August 26. For all of the relevant information, here is your guide for Thursday's Q2... 
Via Benzinga
RedHill Announces Two New U.S. Patents
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Why Redhill Biopharma's Stock Is Trading Higher Today
Redhill Biopharma (NASDAQ:RDHL) shares are tradi... 
Via Benzinga
RedHill Extends Talicia Commercial Coverage
RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx Addition of Talicia® by OptumRx significantly extends Commercial patient access to Talicia® through... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
RedHill Biopharma Ltd Announces RedHill Biopharma Announces Last Patient Out
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Benzinga's Top Ratings Upgrades, Downgrades For May 28, 2021
Upgrades For Delek US Holdings Inc (NYSE:DK), Tudor Pickering upgraded the previous rating of Hold to Buy. For the first quarter, Delek US Hldgs had an EPS of $1.69,... 
Via Benzinga
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be... 
From MicroCap Rodeo
Via AccessWire
Redhill Biopharma: Q1 Earnings Insights
Shares of Redhill Biopharma (NASDAQ:RDHL) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were flat 0.00% year over year to ($0.... 
Via Benzinga
Earnings Outlook for Redhill Biopharma
Redhill Biopharma (NASDAQ:RDHL) releases its next round of earnings this Thursday, May 27. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings... 
Via Benzinga
RedHill's Novel Late-Stage Pills Hold Promise Against COVID-19 and its Variants
Photo by Elsa Olofsson on Unsplash World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus recently said the COVID-19 pandemic's second year was on track to be... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021
Upgrades Janney Montgomery Scott upgraded the previous rating for Centerspace (NYSE:CSR) from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $0.95,... 
Via Benzinga
Earnings Scheduled For May 27, 2021
Companies Reporting Before The Bell • Royal Bank of Canada (NYSE:RY) is likely to report quarterly earnings at $2.48 per share on revenue of $11.77 billion. •... 
Via Benzinga
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Snowflake (NYSE:SNOW... 
Via Benzinga
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
Stocks That Hit 52-Week Lows On Monday
Monday morning saw 78 companies set new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Rocket Companies (NYSE:RKT).... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.